Choose a language and wait for the translated text.
Novo, Lilly, Pfizer and local firm Innovent Biologics are competing for market share with their versions of once-weekly GLP-1 weight-loss injections in China, as the country's National Health Commission has saidthe rate of overweight or obese people could reach more than 65% by 2030.
China's drug regulator accepts Novo Nordisk's application for oral Wegovy | PharmaVoice
